120 related articles for article (PubMed ID: 31793363)
1. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
[TBL] [Abstract][Full Text] [Related]
2. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials.
Xiao Z; Wang CQ; Zhou MH; Li NN; Sun YP; Wang YZ; Liu SY; Yu HS; Li CW; Zeng XT; Chen L; Yao XS; Feng JH
J Immunol Res; 2018; 2018():9081938. PubMed ID: 30648123
[TBL] [Abstract][Full Text] [Related]
3. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients.
Yang L; Ren B; Li H; Yu J; Cao S; Hao X; Ren X
Cancer Immunol Immunother; 2013 Jan; 62(1):65-73. PubMed ID: 22744010
[TBL] [Abstract][Full Text] [Related]
4. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer.
Wang D; Zhang B; Gao H; Ding G; Wu Q; Zhang J; Liao L; Chen H
BMC Cancer; 2014 Apr; 14():251. PubMed ID: 24720900
[TBL] [Abstract][Full Text] [Related]
5. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer.
Qi CJ; Ning YL; Han YS; Min HY; Ye H; Zhu YL; Qian KQ
Cancer Immunol Immunother; 2012 Sep; 61(9):1415-24. PubMed ID: 22290073
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Potential of Cytokine-Induced Killer in Patients with Cancer.
Zhong S; Zhang Y; Lu X; Meftahpour V
J Interferon Cytokine Res; 2024 Mar; 44(3):99-110. PubMed ID: 38488758
[TBL] [Abstract][Full Text] [Related]
7. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
Kyte JA; Trachsel S; Risberg B; thor Straten P; Lislerud K; Gaudernack G
Cancer Immunol Immunother; 2009 Oct; 58(10):1609-26. PubMed ID: 19221745
[TBL] [Abstract][Full Text] [Related]
8. Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma.
Li H; Huang L; Liu L; Wang X; Zhang Z; Yue D; He W; Fu K; Guo X; Huang J; Zhao X; Zhu Y; Wang L; Dong W; Yan Y; Xu L; Gao M; Yang S; Zhang Y
Cancer Immunol Immunother; 2017 Mar; 66(3):299-308. PubMed ID: 27889798
[TBL] [Abstract][Full Text] [Related]
9. Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.
Ren X; Ma W; Lu H; Yuan L; An L; Wang X; Cheng G; Zuo S
Cancer Immunol Immunother; 2015 Dec; 64(12):1517-29. PubMed ID: 26386966
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of postoperative adjuvant transfusion of cytokine-induced killer cells combined with chemotherapy in patients with colorectal cancer.
Zhu Y; Zhang H; Li Y; Bai J; Liu L; Liu Y; Qu Y; Qu X
Cancer Immunol Immunother; 2013 Oct; 62(10):1629-35. PubMed ID: 23974720
[TBL] [Abstract][Full Text] [Related]
11. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.
Durán-Aniotz C; Segal G; Salazar L; Pereda C; Falcón C; Tempio F; Aguilera R; González R; Pérez C; Tittarelli A; Catalán D; Nervi B; Larrondo M; Salazar-Onfray F; López MN
Cancer Immunol Immunother; 2013 Apr; 62(4):761-72. PubMed ID: 23242374
[TBL] [Abstract][Full Text] [Related]
12. DC-CIK cells derived from ovarian cancer patient menstrual blood activate the TNFR1-ASK1-AIP1 pathway to kill autologous ovarian cancer stem cells.
Qin W; Xiong Y; Chen J; Huang Y; Liu T
J Cell Mol Med; 2018 Jul; 22(7):3364-3376. PubMed ID: 29566310
[TBL] [Abstract][Full Text] [Related]
13. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for
Huber A; Dammeijer F; Aerts JGJV; Vroman H
Front Immunol; 2018; 9():2804. PubMed ID: 30559743
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.
Schmeel FC; Schmeel LC; Gast SM; Schmidt-Wolf IG
Int J Mol Sci; 2014 Aug; 15(8):14632-48. PubMed ID: 25196601
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.
Kheshtchin N; Arab S; Ajami M; Mirzaei R; Ashourpour M; Mousavi N; Khosravianfar N; Jadidi-Niaragh F; Namdar A; Noorbakhsh F; Hadjati J
Cancer Immunol Immunother; 2016 Oct; 65(10):1159-67. PubMed ID: 27497816
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide.
Sakakibara M; Kanto T; Hayakawa M; Kuroda S; Miyatake H; Itose I; Miyazaki M; Kakita N; Higashitani K; Matsubara T; Hiramatsu N; Kasahara A; Takehara T; Hayashi N
Cancer Immunol Immunother; 2011 Nov; 60(11):1565-75. PubMed ID: 21681375
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.
Bouet-Toussaint F; Patard JJ; Gervais A; Genetet N; de la Pintière CT; Rioux-Leclercq N; Toutirais O; Thirouard AS; Ramée MP; Catros-Quemener V
Cancer Immunol Immunother; 2003 Nov; 52(11):699-707. PubMed ID: 12879292
[TBL] [Abstract][Full Text] [Related]
18. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.
Meng Y; Yu Z; Wu Y; Du T; Chen S; Meng F; Su N; Ma Y; Li X; Sun S; Zhang G
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28301281
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells: are they clinically relevant?
Palucka K; Ueno H; Roberts L; Fay J; Banchereau J
Cancer J; 2010; 16(4):318-24. PubMed ID: 20693842
[TBL] [Abstract][Full Text] [Related]
20. The critical role of type-1 innate and acquired immunity in tumor immunotherapy.
Ikeda H; Chamoto K; Tsuji T; Suzuki Y; Wakita D; Takeshima T; Nishimura T
Cancer Sci; 2004 Sep; 95(9):697-703. PubMed ID: 15471553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
